# Larazotide in celiac disease: single-dose gluten challenge

Source: https://pepvault.app/research/larazotide-paterson-2007

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Larazotide](https://pepvault.app/research#larazotide)

Randomized trial · people

# Larazotide: no gut permeability rise after gluten in celiac patients

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

This early trial found single doses of larazotide were well tolerated in celiac patients, with no rise in gut leakiness after gluten in the larazotide group.

- **Kind:** Randomized trial
- **Studied in:** People
- **Published:** 2007
- **Journal:** Aliment Pharmacol Ther

## What they tested

The team tested whether 12 mg doses of larazotide (AT-1001) were safe and well tolerated in people with celiac disease who were given gluten.

## How the study was done

A double-blind, randomized, placebo-controlled safety trial in hospital in-patients with celiac disease, comparing single doses of larazotide with placebo (a dummy treatment) during a gluten challenge. Gut permeability, meaning how leaky the intestinal lining is, was measured with lactulose and mannitol urine tests as an exploratory check of whether the drug worked.

<!--promo-->

PepVault for iPhone

## Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Side effects were no more common with larazotide than with placebo. After the gluten exposure, gut permeability rose 70% in the placebo group, while no rise was seen in the larazotide group. Interferon-gamma, a marker of inflammation, went up in 57% of placebo patients compared with 29% of larazotide patients. Gut symptoms showed up more often in the placebo group (P = 0.018).

## What it doesn’t show

This was a small safety study using single doses during a short gluten challenge, so it does not show what happens with longer use. The permeability results were an exploratory measure, not the main goal of the trial.

## The paper

Paterson et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007.

- [PubMed (PMID 17697209)](https://pubmed.ncbi.nlm.nih.gov/17697209/)
- [The paper (DOI 10.1111/j.1365-2036.2007.03413.x)](https://doi.org/10.1111/j.1365-2036.2007.03413.x)

## The compound

- [Larazotide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/larazotide)
- [Larazotide dose guide](https://pepvault.app/lab/dosage/larazotide)

## With this study

### Larazotide

- [Larazotide: the full reference](https://pepvault.app/peptides/larazotide)
- [Larazotide dose guide](https://pepvault.app/lab/dosage/larazotide)

### Studies

- [Larazotide: eased GI symptoms in celiac patients on gluten challenge](https://pepvault.app/research/larazotide-hoilat-2022)
- [All 2 studies](https://pepvault.app/research#larazotide)

### Compared with

- [BPC-157 vs Larazotide](https://pepvault.app/peptides/compare/bpc-157-vs-larazotide)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Larazotide

- [Larazotide: eased GI symptoms in celiac patients on gluten challenge](https://pepvault.app/research/larazotide-hoilat-2022) Meta-analysis · people · 2022
- [Every study on Larazotide](https://pepvault.app/research#larazotide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Larazotide

- [Larazotide: the full reference](https://pepvault.app/peptides/larazotide)
- [Larazotide dose guide](https://pepvault.app/lab/dosage/larazotide)

### Studies

- [Larazotide: eased GI symptoms in celiac patients on gluten challenge](https://pepvault.app/research/larazotide-hoilat-2022)
- [All 2 studies](https://pepvault.app/research#larazotide)

### Compared with

- [BPC-157 vs Larazotide](https://pepvault.app/peptides/compare/bpc-157-vs-larazotide)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Larazotide](https://pepvault.app/research#larazotide)

## The library

- [Larazotide](https://pepvault.app/peptides/larazotide)
- [Larazotide dose guide](https://pepvault.app/lab/dosage/larazotide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
